A robot that lets a doctor remove a stroke-causing blood clot without being in the operating room. Software that replicates, step by step, a cardiologist’s analysis of a heart ultrasound. A protein at the heart of CRISPR, the gene-editing technique now reshaping medicine.
All three trace back to Lithuania, a country of under three million people that is becoming one of Europe’s more productive sources of health innovation.
Behind them sits a life sciences sector that already generates around 3.7% of GDP and roughly €1.5 billion in added value, nearly double the sector’s share when Lithuania first set out to grow it. The national target is 5% by 2030. Life sciences is also one of seven strategic sectors the government has named for 2026–2030, which means sustained policy attention to talent, infrastructure, R&D and financial support.
Robotics and AI moving into the clinic
The mentioned stroke robot belongs to Sentante, which is developing the first fully robotic tele-operated endovascular system. The problem it targets is access. Thrombectomy, the procedure that removes a clot blocking a brain artery, is most effective the sooner it is performed, yet the specialists who carry it out are concentrated in large hospitals. A system that lets them operate remotely could bring that treatment to patients far from those centres.
In 2025, Sentante demonstrated remote robotic stroke thrombectomy in preclinical models, including a pioneering transatlantic procedure, and received FDA Breakthrough Device designation. In 2026, it joined the agency’s Total Product Life Cycle Advisory Program (TAP), which gives developers earlier and more frequent contact with FDA reviewers as they advance towards clinical trials.
Meanwhile, Ligence, the Lithuanian startup behind the heart-ultrasound software, secured a second FDA 510(k) clearance in April 2026, adding fully automated left-ventricular strain analysis. It is not the only Lithuanian AI diagnostics company drawing international interest: Oxipit, whose CE-certified AI reads chest X-rays, chest CT and musculoskeletal images in clinical workflows across Europe, was acquired by Sweden’s Sectra in 2026. Its team was kept on as a dedicated AI development centre in Lithuania.
Gene editing and a new wave of biotech
If robotics and AI show where Lithuanian health innovation is heading, molecular biology shows where it comes from. The CRISPR protein is a case in point: Professor Virginijus Šikšnys’ team was among the first to demonstrate the programmable DNA-cutting capabilities of CRISPR-Cas9, and he has since co-founded the gene-editing company Caszyme. That expertise now underpins an emerging ecosystem for cell and gene therapies and other advanced therapy medicinal products.
A new generation of biotech start-ups is building on that base and drawing international investors. Atrandi Biosciences, which uses proprietary semi-permeable capsules for next-generation single-cell multiomics, raised a $25 million Series A in 2025 led by Lux Capital. Biomatter, whose machine-learning platform designs new proteins, became the first Baltic biotech to join AstraZeneca’s BioVentureHub.
All of this is backed by serious investment. Lithuania spends heavily on biotech R&D for a sector of its size: expenditure equals around 19% of biotechnology value added, ahead of the United States, Ireland and Denmark in a 2024 comparison by Labiotech.
Health data as a testbed
For innovators who need to validate a product, data access can matter as much as funding. Through a single entry point, the State Data Agency facilitates access to Lithuania’s extensive health data resources, which cover more than 95% of the population and span over 20 years, including clinical, prescription, reimbursement and socioeconomic records that can be linked for research. This framework is already largely aligned with the European Health Data Space (EHDS), positioning the country well for its implementation.
The uses span the development cycle, including clinical trial feasibility, patient cohort identification, biomarker research, real-world evidence and post-market safety surveillance. Clinical research builds on the same foundation – AstraZeneca, Roche, Bayer, Sanofi and Novartis are among the companies that have run trials in the country.
A proven manufacturing base
For companies moving from development to production, Lithuania has a track record to point to. Thermo Fisher Scientific and Teva both entered the country by acquiring local companies, Fermentas and Sicor Biotech. Thermo Fisher’s Lithuanian operation has since grown from about 200 to around 1,400 people and combines a global biomanufacturing centre with one of the region’s largest private R&D hubs. During the COVID-19 pandemic it produced key mRNA components for the Pfizer–BioNTech vaccine, from a 5,500 m² facility built in four months.
Thermo Fisher is not an isolated case. Other international manufacturers have followed with investments of their own, among them medtech companies Hollister, Intersurgical and Dexcom and laboratory equipment maker Esco Lifesciences. Local capital is thinking big too – BIO CITY, a biotechnology campus developed by Northway Group, has announced ambitious expansion plans, with projected investment of up to €7 billion over the coming decade.
Whether foreign- or locally owned, nearly all of this capacity serves markets abroad. Around 90% of Lithuania’s life sciences products are exported, with the United States the largest destination, followed by the Netherlands and Germany. With a domestic market of under three million people, facilities in Lithuania are planned for global demand from the outset.
The economics of scaling up
Growth on this scale depends on people, and Lithuania has more scientific capacity than its industry currently uses. Some 21,000 students are enrolled in health and life sciences programmes, yet around 70% of R&D personnel work in academia and the public sector. Business researchers account for just 0.4% of employment, against an EU average of 1.05%. Costs remain competitive: the annual payroll of a 100-person biotech plant is around €1.5 million, compared with roughly €4 million in Ireland and €5 million in Germany.
Beyond talent and costs, the tax system rewards companies that both research and build in Lithuania. R&D costs can be deducted three times from taxable income, and profits from eligible Lithuanian-developed IP are taxed at 7%. Large projects under the Investment Highway framework can qualify for a 0% corporate tax rate for up to 20 years, subject to global minimum tax rules.
The ecosystem is still compact, and its next step is to build stronger links between this research base and larger international players. For companies seeking a European base to develop, validate and scale health technologies, though, Lithuania already offers more of the pieces than its size would suggest.
Picture: Giedrius Akelis, Vilnius TV tower, Lithuania Travel
Source
Invest Lithuania
